A virological benefit from an induction/maintenance strategy: The Forte trial

Antiviral Therapy

Volumn 12, Issue 1, 2007, Pages 47-54

  Asboe, David ^a   Williams, Ian G ^b   Goodall, Ruth L ^c   Darbyshire, Janet H ^c   Hooker, Malcolm H ^c   Babiker, Abdel G ^c  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c MRC CLINICAL TRIALS UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BLOOD DISEASE; CARDIOVASCULAR DISEASE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLACTATEMIA; HYPERTRIGLYCERIDEMIA; LIPODYSTROPHY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MENTAL DISEASE; MOOD DISORDER; NAUSEA; OUTCOME ASSESSMENT; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN ALLERGY; SKIN DISEASE; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING;

EID: 33847391532     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Mocroft A, Legerberger B, Katlama C, et al. Decline in AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22-29.
2. CASCADE Collaboration. Determinants of survival following HIV seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
3. Reijers M, Weverling G, Jurriaans S, et al. Maintenance after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study. Lancet 1998; 352:185-190.
4. Havlir D, Marschner I, Hirsch M, et al. Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. N Engl J Med 1998; 339:1261-1268.
5. Pialoux G, Raffi F, Brun-Vézinet F, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients. N Engl J Med 1998; 339:1269-1276.
6. Clumeck N, Mundere J, Kabeya K, et al. MIRO: a randomized trial of maintenance therapy with or without protease inhibitors after 4 months of triple or quadruple induction therapy. 6th Conference on Retroviruses & Opportunistic Infections. 31 January-4 February 1999, Chicago, IL, USA. Abstract 627.
7. Rutherford G, Sangani P, Kennedy G. Three- or four-versus two-drug antiretroviral maintenance regimens for HIV infection (Cochrane Review). In: The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd; 2004. Issue 2.
8. EMEA. Topic E2D Note for Guidance on Definition and Standards for Expedited Reporting (CPMP/ICH/3945/03) November 2003 [cited 2005 Mar 22]. Available from: http://www.emea.eu.int/pdfs/human/ich/ 394503en.pdf.
9. Johnson V, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med 2004; 12:119-124.
10. Fischl M, Ribaudo H, Collier A, et al. A randomised trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis 2003; 188:625-634.
11. Shafer R, Smeaton L, Robbins G, et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003; 349:2304-2315.
12. Loveday C, Grant P, Goodall R, et al. for the FORTE Virology Group and Trial Steering Committee. Adding a PI for 6 months to a standard NNRTI-based regimen reduces the risk of virological failure without inducing resistance to the PI: a FORTE virology analysis. 12th Conference on Retroviruses & Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract P575.
13. van Leth F, Andrews S, Grinsztein B, et al. for the 2NN Study Group. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 2005; 19:463-471
14. Gallant JE, Dejesus E, Arribas JR, et al. for the Study 934 Group. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354:251-260.